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SUMMARY
To investigate the mechanisms underlying
motor hyperactivity, we performed intra-
cisternal injection of 6-hydroxydopamine or
endocrine disruptors in rats on postnatal day 5.
6-Hydroxydopamine (100 ttg, 488 nmol) caused
a significant increase in spontaneous motor
activities at 4 weeks of age. Gene-expression
profiling using a cDNA membrane array
revealed alterations in several classes of gene at
8 weeks of age. In the midbrain, gene expression
was enhanced in dopamine transporter1; a
platelet-derived growth factor receptor;
dopamine receptor D4; galanin receptor 2;
arginine vasopressin receptor 2; neuropeptide Y;
tachykinin 2; and fibroblast growth factor 10.
Expression was also enhanced in the
glutamate/aspartate transporter gene in the
striatum. Rats received an endocrine disruptor
(87 nmol), such as bisphenol A, nonylphenol, p-
octylphenol, or diethylhexylphthalate, which
also caused motor hyperactivity at 4 weeks.
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The effects of bisphenol A on motor activity
were dose-dependent from 0.87 to 87 nmol. The
phenols caused a deficit in dopamine neurons,
similarly to the deficit caused by 6-hydroxy-
dopamine. Gene-expression profiles after
treatment with endocrine disruptors showed
variation and differed from those of 6-
hydroxydopamine. The results suggest that
neonatal treatment with environmental
chemicals can generate an animal model of
attention-deficit hyperactivity disorder, in
which clinical symptoms are pervasive.
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INTRODUCTION
Patients with attention-deficit hyperactivity
disorder (ADHD) show inattention, motor hyper-
activity, and impulsivity. Although ADHD is
known as a developmental disorder, the etiology is
not yet clear. To understand the mechanisms of
ADHD, a number of studies have been performed
in several kinds of animal models showing
genetically derived hyperactivity or naturally
occurring behavioral variability. Lesion studies
and pharmacological treatment were also reported
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(Viggiano, 2003). Although the mesocorticolimbic
dopamine (DA) system has been suggested to be
involved in ADHD, whether the DA system is
hypo- or hyper-functioning remains to be elucidated.
Because treatment with methylphenidate often
attenuates hyperactivity (Swanson, 2003), a
hyperkinetic child with neonatal 6-hydroxydopa-
mine (6-OHDA) lesions (Shaywitz, 1976a, b) is a
valuable model ofADHD in view ofmotor activity.
Rats with a deficit in the development of DA
neurons show motor hyperactivity during the
juvenile period (Davids, 2002a; Heffner, 1982;
Shaywitz, 1976a, b; Zhang, 2001), which can be
attenuated by psychostimulants like those used to
treat clinical ADHD (Swanson, 1998; Volkow,
2002).
It has been demonstrated that exposure to
environmental chemicals that mimic the action of
estrogen disrupts endocrine function (Markey, 2002).
Most of these compounds, the so-called endocrine
disruptors (EDs), are derived from industrial
products and have been detected in the human
umbilical cord and cord serum (Mori, 2001).
Several lines of evidence suggest that estrogen
affects the central DA system (Kuppers, 2001).
However, the effects of EDs on the central nervous
system have not been well documented. Therefore,
it would be of interest to study the effects of
neonatal treatment with EDs on the DA system and
on spontaneous motor activity (SMA) in the rat.
To understand the mechanisms underlying
motor hyperactivity caused by the lack of a meso-
eortieolimbie DA system, we generated neonatal
6-OHDA lesions in the rat. The effects of neonatal
treatment with EDs, such as bisphenol A, nonyl-
phenol, p-oetylphenol and diethylhexylphthalate
(DEHP), were also studied to examine whether
these chemicals can exert effects on brain function,
as shown for other environmental chemicals
(Palanza, 1999). Spontaneous motor activity was
measured at 4 weeks of age, a juvenile period. The
expression of multiple genes was analyzed by the
eDNA maeroarray method using a nylon membrane
array in the striatum and midbrain. This method
provides results that are more reproducible than the
microarray, and several groups have applied this
method to their studies on the central nervous
system (Cho, 2002; Hida, 2003; Napolitano, 2002)
and PC12 cells (Foehr, 2000). lmmunohistochemical
studies were also performed for the detection of
tyrosine hydroxylase (TH) to examine the integrity
ofDA neurons in the midbrain.
EXPERIMENTAL
Treatment ofanimals
The present study was conducted in
accordance with the Guidelines for the Care and
Use of Laboratory Animals in the National
Institute of Advanced Industrial Science and
Technology, Japan, and in the National Institute
for Environmental Studies, Japan. Female Wistar
rats were purchased from Clea Japan (Tokyo,
Japan) 2 weeks after becoming pregnant. The rats
were individually housed in an acrylic cage at
22C with tap water and laboratory chow
(Oriental Yeast Corp., Tokyo, Japan) ad libitum.
The breeding room was illuminated from 07:00 to
19:00 h in 12-h cycles.
Male pups were selected at 5 days after birth.
The body weight of the animals was-10 g.
Desipramine (Sigma-Aldrich, St. Louis, Missouri,
USA), a blocker of noradrenaline (NA) uptake,
was administered intraperitoneally at 25 mg/kg
body wt to protect adrenergic neurons from the
effects of 6-OHDA. Thirty minutes later, the rats
received 100 micrograms (488 nmol) of 6-OHDA
hydrobromide (Sigma-Aldrich) in 0.9% NaCI
containing 0.04% ascorbic acid (10 microliters)
intracistemally. For controls, the vehicle was
injected under similar conditions. We also
performed an intracistemal administration of EDs,
purchased from Wako Pure Chemical Ind. (Tokyo,
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such as bisphenol A, nonylphenol, p-octylphenol,
or DEHP, was dissolved in olive oil (Nacalai
Tesque, Kyoto, Japan) to 8.7 mM. The pups
received an intracisternal injection of 87 nmol in a
volume of 10 microliters. In some experiments,
bisphenol A was dissolved from 0.087 to 87 nmol
in 10 microliters. For the control, the same volume
of olive oil was injected intracisternally under
similar conditions. Next, the pups were randomly
assigned to lactating dams, 5-7/dams and weaned
at 3 weeks of age.
Measurement ofspontaneous motor activity
We measured the SMA of 4-5 week-old rats
using the Supermex activity-monitoring system
(Muromachi Kikai, Tokyo, Japan), as described
previously (Ishido, 2002; Masuo, 1995). Briefly,
each rat was placed in a transparent plastic home
cage (24 x 30 x 18 cm, width x depth x height),
located in a sound-attenuating chamber (45 x 50 x 45,
internal width x depth x height) illuminated in a 12
h/12 h light/dark cycle (light: 7:00-19:00). A
Supermex sensor box (83 x 53 x 35 mm, width x
depth x height) mounted in the center of the ceiling
of a sound-attenuating chamber detected motor
activity, and sensor signals were transmitted by an
interface device (DI-032), to a personal computer.
The signals were converted to the number of
movements with CompACT AMS software.
Brain dissection
The rats were decapitated at 8 or 10 weeks of
age, and whole brains were rapidly removed and
put on an ice-cold glass plate with the ventral
surface upward. The olfactory tubercles were first
dissected from both hemispheres. Next, the frontal
cortex was separated from the olfactory bulb with
a transverse section at the level of the posterior
limb of the frontal cortex. After the olfactory
bundle and hypothalamus were removed, the rest
of the brain was placed with the dorsal surface
upward. Both hemispheres were separated to the
depth of the corpus callosum and the lateral
ventricle was exposed. The cerebral cortex and
striatum in each hemisphere were removed and the
striatum was gently separated from the cortex.
Other limbic areas containing the nucleus
accumbens and septum were separated by the
following sections from the rest of the brain: a
section at the plane between the ventral edge of the
lateral ventricle and the anterior commissure, a
transverse section at the posterior limb of the
septum, and a transverse section at the level of the
posterior limb of the frontal cortex as described
above. The region removed was combined with the
olfactory tubercles previously dissected. The
midbrain was dissected using transverse sections
from the rest of the brain at the anterior and
posterior limbs of the substantia nigra. All tissue
samples were frozen in liquid nitrogen and stored
at-80 C.
Catecholamine contents
Catecholamine levels were measured in the
frontal cortex, the striatum, and in other limbic
areas containing the nucleus accumbens and the
septum and olfactory tubercles in rats at 10 weeks
of age. Each tissue sample was homogenized in 0.5
mL of 0.2 M perchloric acid containing 100 tM
EDTA-2Na and 100 ng of isoproterenol (internal
standard). Atter centrifugation at 20,000 x g for 15
min, the supernatant was transferred to another
tube and the pH was adjusted to 3 by adding M
sodium acetate. After filtration through a filter
having an average pore diameter of 0.45 tm, the
samples were subjected to high-performance liquid
chromatography (HPLC). The catecholamines
were separated using a reverse-phase column, 4.6
x 150 mm, Eicompak MA-5ODS (Eicom, Kyoto,
Japan) maintained at 25 C. The mobile phase was
a 0.83 M citrate-sodium acetic acid buffer, pH 3.5,
containing 230 mg/L of octane-sulfonic acid,
5 mg/ L of EDTA-2Na, and 17% methanol at a.62 YOSHINORI MASUO ET AL.
flow rate of 1.0 mL/min. Dopamine and NA were
detected by an electrochemical detector (ECD-100,
Eicom) at +750 mV vs. Ag/AgCI. The respective
retention times for NA, DA, and isoproterenol
were 5.2, 11.0, and 14.5 minutes. The results were
calculated as nanograms per milligram ofprotein.
Immunohistochemistry
In some experiments, the whole brain was
immediately removed after the decapitation of
8-week-old rats. Each brain was fixed with 10%
(vol/vol) phosphate-buffered formalin, pH 7.2, and
embedded in paraffin. The tissue was cut into 5-
micrometer-thick serial sections using a microtome
and processed for immunohistochemical staining
using avidin-biotin alkaline phosphatase. Briefly,
sections were permeabilized with 5 mL/L Triton
X-100 in phosphate-buffered saline (PBS) and
blocked for 30 min with 100 g/L normal horse
serum and 40 g/L bovine serum albumin at 4 C.
Next, the sections were incubated with the primary
monoclonal antibody anti-tyrosine hydroxylase (TH)
(1:100; Sigma-Aldrich) in the presence of 40 g/L
bovine serum albumin and 0.5 mL/L Triton X-100.
After washing with PBS containing mL/L Tween
20, the sections were incubated with a biotinylated
secondary antibody, goat anti-mouse IgG (Lab Vision
Corp., Fremont, California, USA). The biotinylated
molecules were further incubated for 10 min with
streptavidin-conjugated alkaline phosphatase at
room temperature. Tyrosine hydoxylase immuno-
reactivity was visualized with 5-bromo-4-chloro-3-
indolyl phosphate/nitroblue tetrazolium (Lab Vision
Corp.) and counterstained with 1% methyl green.
DNA array analysis
For the investigation of muitiple-gene
expression, the striatum and midbrain from
8-week-old rats were processed to the eDNA
macroarray according to the manufacturer’s
protocol (BD Biosciences Clontech, Palo Alto,
California, USA). Two striata taken from both
hemispheres in one rat were pooled as one sample
(-60 mg) and the midbrain obtained from one rat
(-80 mg) was used as one sample. We dissected
the whole midbrain rather than the ventral mesen-
cephalon containing the substantia nigra and
ventral tegmental area (VTA) as more than 50 mg
of tissue was required to perform the cDNA
macroarray. Total RNA was extracted from the
tissue sample and quantified by UV spectroscopy;
the quality was estimated by capillary electro-
phoresis. After reverse transcription, the eDNA
probe was labeled with [ct-32p]dATP, PB 10204
(110 TBq/mmol, Amersham Bioscience, Piscataway,
New Jersey, USA) and hybridized with an Atlas
Rat 1.2 Array (BD Biosciences Clontech). The
array consisted of a nylon membrane on which
1,176 kinds of eDNA were spotted. In each
experiment, one array membrane was used for one
sample. Radiolabeled membranes were exposed to
imaging plates (Fujifilm, Tokyo, Japan) and gene
expression intensities were analyzed using the
Fluorescent Image Analyzer FLA-3000G (Fujifilm)
and the Atlaslmage software (BS Biosciences
Clontech). We performed 3 experiments with 3
rats independently and calculated the mean value
of the gene-expression ratio of the sham-operated
controls. The differences in gene expression were
considered above the threshold when the signal
intensities differed by more than 3 and the
expression ratios differed by more than 1.69.
Statistical analysis
The effects of treatment with 6-OHDA or EDs
on SMA were examined by analysis of variance
(ANOVA) of repeated measure. Among four kinds
of ED, the effects were compared by two-way
ANOVA, followed by post-hoe Scheff6 test for
planned comparisons. For catecholamine levels,
Student’s t-test was applied to determine theMOTOR ACTIVITY AND GENE EXPRESSION IN THE RAT 63
TABLE 1
Effects ofneonatal treatment with 6-OHDA on endogenous catecholamine levels in the rat brain
Limbic area without
Catecholamine Frontal cortex Striatum striatum
Dopamine
Control
Treated
Noradrenaline
Control
Treated
1.41 + 0.29 (6) 126.04 4- 10.97 (6) 50.53 4- 5.79 (6)
0.80 4- 0.11 (16)* 3.67 4- 0.63 (16)** 11.50 4- 1.35 (16)**
-43.3% -97.1% -77.2%
6.27 4- 0.56 (6)
6.42 4- 0.52 (16)
-1.90 4- 0.17 (6)
1.76 4- 0.17 (16)
23.71 4- 1.16 (6)
27.51 4- 2.44 (16)
Rats received intracistemal administration of 6-OHDA aRer intraperitoneal injection of desipramine at 5 days of
age. At 10 weeks of age, rats were sacrificed and cateeholamine levels were measured by HPLC-ECD in the
frontal cortex, striatum, and other limbie area (septum, nucleus aeeumbens, and olfactory tubercles). Results are
expressed as ng/mg protein, and mean+/-S.E.M. (number ofrats).
* P < 0.05, ** P < 0.01 vs. respective control value (Student’s t-test).
significance of the differences between values
obtained in rats with neonatal treatment and the
respective sham-operated controls. According to
the two-tailed probability, p < 0.05 was considered
statistically significant.
RESULTS
Endogenous catecholamine levels after neonatal
treatment with 6-OHDA
We injected 6-OHDA intracistemally into the
rat at 5 days of age and the catecholamine contents
were measured by HPLC-ECD. As shown in
Table 1, neonatal treatment with 6-OHDA
significantly decreased the endogenous levels of
DA in the frontal cortex, striatum, and other limbic
areas containing the nucleus accumbens, septum,
and olfactory tubercles in rats at 10 weeks of age.
Among these regions, decreases ofDA levels were
most significant in the striatum. The levels were
diminished by 97% in this region. DA contents in
the lesioned rats were significantly lower than in
the controls by 43% and by 77% in other limbic
areas and in the frontal cortex, respectively. The
endogenous levels of NA did not show any
significant changes in either region.
Effects of neonatal 6-OHDA lesions on SMA in
juvenile rats
As shown in Fig. 1, SMA showed high levels
during the dark phase and low counts during the
light phase. In the sham-operated control rats
(n 14), SMA was 5020+/-465 counts (mean+/-
SEM) in the first 2 h of the dark phase, but these
levels had recovered by 8 h to 2624 + 297. The
activity levels were then enhanced again, peaking at
12 h (3503 + 276). By contrast, the rats showed low
levels of SMA during the light phase from
473 + 84 to 1480+ 198. The SMA in 6-OHDA-
treated rats (n 14) was significantly higher than64 YOSHINORI MASUO ET AL.
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Fig. 1: Effects ofneonatal treatment with 6-OHDA on spontaneous motor activity (SMA) at 4 weeks ofage. Male
Wistar rats received intraperitoneal injections ofdesipramine (25 mg/kg) followed by intracisternal
administration of6-OHDA (100 tg in 10 tL). Controls received 10L ofthe vehicle used for 6-OHDA (0.04%
ascorbic acid in saline). SMA was measured using a Supermex system (Muromachi Kikai, Tokyo, Japan) at 4-5
weeks ofage in a 12h/12h light/dark cycle. Upper: results represented as mean + SEM (n number of animals)
ofcounts per 2 h. The period oftime 0-12 was the dark phase. Lower: the counts ofSMA accumulated during
24 h or 12 h periods in rats (number of animals). SMA in 6-OHDA-treated rats was significantly higher than
that in controls during a 24 h period and in the dark phase; P 0.0004 and P < 0.0001, respectively, by
ANOVA ofrepeated measure.MOTOR ACTIVITY AND GENE EXPRESSION IN THE RAT 65
in controls during a 24 h period [F(1,286) 16.622,
P 0.0004 by ANOVA of repeated measure] and in
the dark phase [F(1,130) 20.741, P 0.0001 ]. The
differences between the 6-OHDA-treated and the
ontrol rats were not statistically significant during the
light phase [F(1,130) 0.129, P 0.7223]. Thus,
neonatal treatment with 6-OHDA did not cause a
modification in motor activity with the day-night
cycle. The general behavior in rats with 6-OHDA
lesions did not differ from that of controls. Indeed, an
increase in rearing behavior was not evident, although
we did not quantify the rearing. Moreover, stereo-
typed behavior was not observed aider treatment with
6-OHDA.
Effects of neonatal treatment with EDs on SMA in
juvenile rats
We also measured SMA after neonatal
treatment with EDs. Figure 2 shows SMA in rats at
4 weeks of age after treatment with bisphenol A.
The pattern of SMA in sham-operated control rats
(n 7) was similar to that of the controls for 6-
OHDA-lesioned animals. Bisphenol A caused a
dose-dependent increase in SMA. With 87 nmol of
bisphenol A (n 6), the differences between the
treated and control animals were statistically signifi-
cant during 24 h [F(1,121) 47.692, P < 0.0001], in
the dark phase [F(1,55)= 44.375, P < 0.0001] and
10.o Bisphenol A 87 nmol (n=6)
--*-- Bisphenol A 8.7 nmol (n=6)
--=- Bisphenol A 0.87 nmol (n=6)
8.0 ----
Bisphenot A 0.087 nmol (n=6)
-<>- Control (n=7)
6,0 ""m
4.0 .
0 2 4 6 8 10 12 14 16 18 20 :22 24
Time (h)
x
4O
<
30
II 12 h (dark phase)
I 12 h (light phase)
Control 0,087 0.87 8,7 87
(n=7) (n=6) (n=6) (n----6) (n=6)
Blsphenol A (nmol)
Fig. 2: Effects of neonatal treatment with
bisphenol A on SMA at 4 weeks of
age. Bisphenol A dissolved in 10
tL of olive oil was injected into
male rats intracisternally at 5 days
of age. Controls received the
vehicle. SMA was measured as
described in Fig. 1. Upper: results
expressed as mean+ SEM (n=
number of rats) of counts per 2 h.
Lower: the counts of SMA during
24 h or 12 h periods in rats (number
of animals). SMA in bisphenol A-
treated rats was significantly higher
than that in controls at doses from
0.87 to 87 nmol during either period
(p< 0.05 by ANOVA of repeated
measure). 0.087 nmol of bisphenol
A did not cause significant changes
in SMA.66 YOSt/INORI MASUO ET AL.
light phase [F(1,55) 24.746, P 0.0004]. SMA
was also enhanced after treatment with 8.7 nmol of
bisphenol A (n 6).
Significant differences were found between the
two groups during 24 h [F(1,121)=19.318,
P 0.0011 ], in the dark phase [F(1,55) 20.589,
P=0.0008] and light phase [F(1,55) 12.319,
P= 0.0049]. The lower dose, 0.87 nmol (n =6),
also caused significant increases during 24 h
[F(1,121) 10.818, P 0.0072], in the dark phase
[F(1,55) 4.890, P 0.0491] and light phase
[F(1,55) 6.325, P 0.0287]. SMA levels were
not significantly increased in rats treated with
0.087 nmol of bisphenol A (n 6) during 24 h
[F(1,121) 0.005, P 0.9454], in the dark phase
[F(1,55) 0.017, P 0.8990] and light phase
[F(1,55) 0.014, P 0.9085].
Fig.3 shows SMA in 4-week-old rats after
neonatal treatment with 87 nmol of nonylphenol,
p-octylphenol, or DEHP. All chemicals caused
motor hyperactivity, not only during the dark
phase but also during the light phase. A significant
difference was not found among these three
chemicals and bisphenol A at 87 nmol during 24 h
[F(3,209) 1.356, P--0.2863], in the dark phase
[F(3,95) 1.952, P 0.1555] and in the light phase
[F(3,95) 0.860, P 0.4786]. As shown in Fig. 4,
treatment with bisphenol A, nonylphenol, p-octyl-
phenol, or DEHP significantly enhanced SMA.
The differences between bisphenol A-treated and
control animals were statistically significant during
24 h [F(l, 121) 66.733, P < 0.0001 ], in the dark
phase [F(1,55)= 50.343, P < 0.0001] and in the
light phase [F(1,55) 15.858, P 0.0022], although
the control rats were not the same as those in Fig.
2. With nonylphenol, hyperactivity was significant
during 24 h [F(1,132)=26.467, P=0.0002], in
the dark phase [F(l,60)- 17.399, P- 0.0013] and
light phase [F(1,60) 9.700, P 0.0089].
The effects ofp-octylphenol were evident during
24 h [F(l,l 10) 44. l, P < 0.0001 ], in the dark
phase [F(l,50) 28.024, P 0.0004] and light phase
[F(l,50)-- 14.060, P 0.0038]. SMA in rats treated
with DEHP significantly differed from controls
during 24 h IF(l,110)= 250.751, P < 0.0001], in the
dark phase IF(l,50)= 107.430, P < 0.0001] and light
phase [F(1,50) 27.246, P 0.0004]. Nonylphenol
in particular however, caused hyperactivity at the first
2 h of the dark phase (Fig. 3, P < 0.0001, Student’s
t-test). Among the other EDs, bisphenol A induced a
slight but significant increase (P 0.0319) with no
statistical alterations with p-octylphenol and DEHP.
Similar to the effects of the 6-OHDA lesions, the
general behavior in rats with neonatal ED treatment
was normal. For example, rearing behavior and
stereotyped behavior were not evident.
Tyrosine hydroxylase immunoreactivity
We performed immunohistochemistry for TH.
As shown in Fig. 5, in control rats, strong TH
immunoreactivity was observed in the VTA and
the SNC. Neonatal treatment with nonylphenol
and p-octylphenol clearly attenuated the immuno-
reactivity in these regions. Treatment with 6-OHDA
and bisphenol A also diminished TH immuno-
reactivity (lshido, 2004). On the other hand, DEHP
did not alter the immunoreactivity in either region
(data not shown).
Multiple gene expression
The integrity of total RNA extracted from the
brain was examined in all samples. A ratio of the
yield of RNA/tissue weight was at least 1.00xl0
-3
and OD 260 nm/280 nm of the RNA was not less
than 2.0. After electrophoresis of RNA, rRNA
subunit bands at 18S and 28S indicated the
presence of intact RNA. Indeed, the 28S/18S ratio
of rRNA was around 1.5. The hybridization
intensities were calculated for every gene on the
array for control and treated animals, and a ratio of
the summed intensities was made.
Tables 2 and 3 show altered gene expression
in the midbrain and striatum in rats exposed to
neonatal treatment with 6-OHDA, bisphenol A,MOTOR ACTIVITY AND GENE EXPRESSION IN THE RAT 67
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Fig. 3: Effects of neonatal treatment with
nonylphenol, p-octylphenol, or DEHP
on rat SMA. Each chemical compound
(87 nmol) dissolved in 10 pL of olive oil
was injected intracisternally at 5 days of
age. The vehicle was similarly injected
for controls. SMA was measured at 4
weeks of age as described in Fig. 1.
Results are represented as counts per 2 h
and are means +/- SEM (n=number of
animals). All of these chemicals caused
significant motor hyperactivities during
a 24 h period (p<0.001 by ANOVA of
repeated measure).68 YOSHINORI MASUO ET AL.
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Fig. 4: SMA in rats with neonatal treatment with
EDs. Bisphenol A, nonylphenol, p-
octylphenol, or DEHP at the dose of 87
nmol/10 laL was injected into the rat
intracistemally at 5 days of age. SMA
was measured at 4 weeks of age as
described in Fig. 1. Results are expressed
as counts of SMA during 24 h or 12 h
periods and are means ::: SEM (number
of animals). The effects of bisphenol A
presented in this figure were examined
independently of Fig. 2. All of these
chemicals caused significant motor
hyperactivities during the dark and light
phases (p<0.01 by ANOVA of repeated
measure).
Fig. 5: TH immunoreactivity in the VTA
and substantia nigra pars compacta
(SNC) in rats treated with
nonylphenol or p-octylphenol.
Sagittal sections were made from the
brain of rats at 8 weeks of age and
processed to immunohistochemistry
for TH using avidin-biotin alkaline
phosphatase. TH immunoreactivities
were visualized with 5-bromo-4-
chloro-3-indolyl phosphate/nitroblue
tetrazolium and counterstained with
methyl green. TH immunoreactivites
were highly observed in the SNC and
VTA in control animals. Neonatal
treatment with nonylphenol and p-
octylphenol attenuated the
immunoreactivities in these regions.
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nonylphenol, p-octylphenol, and DEHP. The results
are expressed as an expression ratio, with gene
expression in treated rats per sham-operated
controls. Each value is the mean of results from
three sets of experiments (n 3 animals). The
tables list the genes in which the expression was
above the threshold (signal intensities differed by
more than 3 and expression ratios differed by more
than 1.69) in rats treated with 6-OHDA. Therefore,
no change (-) and not determined because of low
intensities of gene expression (ND) are contained
in EDs-treated animals. All the DA-related genes
contained in the Atlas Rat 1.2 are represented,
even if the expression was not altered by either
chemical compound.
As shown in Table 2, increased expression was
observed in the midbrain after neonatal 6-OHDA
lesions in the c-fos proto-oncogene, Cyp4f6, Datl,
Nhe 1, Atp12a, Sop2, Hsd3b, Cyp 17, Tkl, Hspal a,
Pdgfrb, Insr, Drd4, Galr2, Avpr2, Npy, Tac2, Grp,
Fgfl0, Nppc, and in Igfbp6. Among the EDs,
bisphenol A did not change the expression of genes
for which 6-OHDA lesions caused alterations.
Nonylphenol and p-octylphenol increased only Nppc
expression. On the other hand, treatment with DEHP
enhanced the expression of Glast, Sod l, HSP90-beta,
Npy, Fgfl0, and Nppc. Table 3 shows altered gene
expression in the striatum. 6-OHDA lesions increased
the expression of Scnlb, Glast, Atp61, Sod l, and
HSP90-beta. No change was observed atter treatment
with nonylphenol and DEHP. p-Octylphenol induced
Cyp4f6 and Galr2.
DISCUSSION
After treatment with 6-OHDA, the endogenous
contents of DA were significantly lower than those
in the controls in the frontal cortex, striatum, and in
other limbic areas, such as the nucleus accumbens,
septum, and olfactory tubercles. Dopamine levels
were almost completely abolished in the striatum.
Nevertheless, NA levels did not show significant
changes in either region, indicating that the
adrenergic neurons might be intact because of
desipramine pretreatment. The DA-specific lesions
caused significant increases in SMA at 4-5 weeks of
age, similarly to the results of our previous studies
(Masuo, 2002). Yet, the degree of increment of
SMA is lower than that in previous studies (Davids,
2002b; Zhang, 2001, 2002), and significant changes
were not observed during the light phase. This
variation might be due to different methods used for
measuring motor activity. We detected all kinds of
motor behavior during 24 h under the 12-h dark and
12 h-light conditions, which can result in adaptation
to the environment. In previous studies by other
groups, the locomotor activity was detected for 90
min during the light phase in a novel environment to
investigate reactivity to the novelty ofthe situation.
Similarly, SMA was increased by neonatal
treatment with bisphenol A, nonylphenol, p-octyl-
phenol, and DBP. Hyperactivity was significant
not only during the dark phase but also during the
light phase. The results of this experiment suggest
that EDs can cause a deficit in sleep. The
day/night cycle was maintained, however, because
a rhythm shift was not observed. Nonylphenol-
induced hyperactivity was extremely high at the
first 2 h, suggesting that these rats might have
difficulty in adapting to a novel environment.
Indeed, rats passed the dark phase in a sound-
attenuating chamber for the first time. The
hyperactivity during the 24 h period after EDs
treatment raises the question of whether EDs are
more potent than 6-OHDA in inhibiting the
development of DA neurons or whether the
mechanisms of EDs-induced motor hyperactivity
differ from those of 6-OHDA lesions. The former
may be not the case, however, because rats with
6-OHDA lesions in which the endogenous DA
contents were almost completely abolished did not
show hyperactivity in the light phase.
The results of the behavioral studies prompted us
to perform immunohistochemistry for TH. We found
an attenuation in immunoreactivity in the VTA and70 YOSHINORI MASUO ET AL.
TABLE 2
Gene expression in the midbrain altered by 6-OHDA or EDs
Classification, Gene name Expression ratio
6-OHDA Bisphenol A Nonylphenol F-Octylphenol
3.67
4.67
14.11
DEHP
Transcription
c-los proto-oncogene 3.00 0.45
Stress response proteins
Cytochrome P450 4F6 (Cyp4f6) 3.00
Membrane channels and transporters
Na+ channel, voltage-gated, type 1, beta polypeptide (Scnlb) 0.32
S1c6a3; Dopamine transporter (Dat1) 2.29 0.35
Sle9al; Na+/H+ exchanger (Nhel) 3.43
Slea3; Glutamate/aspartate transporter (Glast) 0.50
H+-ATPase, lysosomal (vacuolar proton pump) 16 kDa (Atp61) 0.35
I-I+/K+-ATPase, nongastrie, alpha polypeptide (Atp12a) 9.20 0.54
Metabolism
Superoxide dismutase (Sod1) 0.44
Sterol carrier protein 2, liver (Scp2) 5.27 0.43
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid
delta-isomerase (Hsd3b)
Cytochrome P450, subfamily 17 (Cyp17)
Thymidine kinase (Tkl)
Post-translationalmodificationfolding
Heat shock 90-kDa protein beta (HSP90-beta) 0.37
Heat shock 70kD protein 1A (Hspal a) 1.73
Cell receptors (by ligands)
PDGF receptor, beta polypeptide (Pdgfrb) 5.67
Insulin receptor (Insr) 2.00
Dopamine receptor 1A (Drdla) ND
Dopamine receptor 2 (Drd2) ND
Dopamine receptor D4 (Drd4) 1.90
Galanin receptor 2 (Galr2) 2.33 0.43
Neurotensin receptor 2 (Ntsr2) 0.39 ND
Arginine vasopressin receptor 2 (Avpr2) 2.75 0.44
Glutamate receptor, ionotropie,NMDA (Grinl) 0.56 0.59
Cell signaling, extracellular communicationproteins
Neuropeptide Y (Npy) 2.33
Taehykinin 2 (Tae2) 7.86
Gastrin-releasing peptide (Grp) 2.67
Fibroblast growth factor 10 (Fgfl0) 5.67
Somatostatin (Sst) 0.43
Natriuretie peptide precursor C (Nppe) 2.15 2.27
Insulin-like lrowth factor binding protein 6 (IgfbP6) 2.00
0.52
2.30
2.27
0.18
2.29
0.29
0.48
ND ND
0.26
0.25
0.41
4.00
0.50 3.54
2.14 2.31
Multiple gene expression was examined by cDNA macroarray. Each value represents the ratio ofgene expression level versus that
ofrespective control value. This table lists the genes for which expression was above the threshold (expression ratios differed by
more than 1.69 for an increment, less than 0.59 for a decrement) in rats treated with 6-OHDA. All the DA-related genes contained
the Atlas Rat 1.2 are also listed. -, no change; ND, not determined since the density ofgene expression was too weak to detect an
alteration in the expression; Sic, solute carrier family; PDGF, platelet-derived growth factor.MOTOR ACTIVITY AND GENE EXPRESSION IN THE RAT 71
TABLE 3
Gene expression in the striatum altered by 6-OHDA or EDs.
Classification, Gene name
Expression ratio
6-OHDA Bisphenol A Nonylphenolp-Octylphenol DEHP
Transcription
c-fos proto-oncogene
Stress response proteins
Cytochrome P450 4F6 (Cyp4f6)
Membrane channels and transporters
Na channel, voltage-gated, type 1, beta polypeptide (Scnlb)
S1c6a3; Dopamine transporter (Datl)
Slc6al 1; GABA transporter (Gat3)
Slca3; Glutamate/aspartate transporter (Glast)
H+-ATPase, lysosomal (vacuolar proton pump) 16 kDa (Atp61)
Aquaporin 3 (Aqp3)
Metabolism
Superoxide dismutase (Sod 1)
Sterol carrier protein 2, liver (Scp2)
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid
delta-isomerase (Hsd3b)
Cytochrome P450, subfamily 17 (Cyp 17)
Post-translationalmodificationfolding
Heat shock 90-kDa protein beta (HSP90-beta)
Heat shock 70kD protein 1A (Hspala)
Cell receptors (by ligands)
PDGF receptor, beta polypeptide (Pdgfrb)
Galanin receptor 2 (Galr2)
Glutamate receptor, ionotropic, NMDA (Grinl)
Dopamine receptor IA (Drdla)
Dopamine receptor 2 (Drd2)
Dopamine receptor 4 (Drd4)
Cell signaling, extracellular communication proteins
PDGF, B polypeptide (Pdgfb)
0.33 0.46
0.38 ND 1.89 ND
2.33
0.36 ND
0.37
1.88
2.50
0.42 ND
0.59
2.25 0.50
0.35
0.47
ND
0.41 0.57
0.46 ND ND
2.27
0.48 0.43 0.43
0.33 ND
0.30 0.50 1.76 0.50
0.40 0.10
ND ND
ND ND
ND ND ND
0.48 0.55
Results are represented as in Table 2.
substantia nigra pars compacta induced by nonyl-
phenol and p-octylphenol. Similar results were found
in rats treated with bisphenol A (Ishido, 2004).
Therefore, these phenols may cause a deficit in the
development of mesocorticolimbic DA neurons.
Endogenous catecholamine levels should be further
measured after these treatments. Furthermore,
bisphenol A might induce apoptosis in central neural
cells (Oka, 2003). Bisphenol A and nonylphenol
stimulate hydroxy radical generation in the rat
striatum (Obata, 2000). Taken together, neonatal
treatment with phenols can cause neuronal cell death
by stimulating hydroxy radical formation, as seen in
the effects of6-OHDA (Ferger, 2001), and 1-methyl-72 YOSHINORI MASUO ET AL.
4-phenylpyridinium ion (MPP/) (Obata, 2001).
Diethylhexylphthalate treatment, however, did
not cause a significant change in TH immuno-
reactivity in these regions. Thus, the mechanisms
underlying hyperactivity might not be identical
among EDs. Such different effects of EDs on DA
neurons might result in a clinical variation of
ADHD. It would be of interest to examine the
effects of psychostimulants on the hyperactivity
caused by EDs. Motor hyperactivity caused by
hypofunction of DA might be attenuated by
methylphenidate (Swanson, 1998; Volkow, 2002).
Hyperactivity is also observed in methylphenidate-
insensitive ADHD, however. The different effects
of EDs can provide animal models for such
clinical variation in this disorder.
To understand the mechanisms of hyper-
activity, we first performed a cDNA array, using
an Atlas Rat 1.2 membrane array manufactured by
BD Biosciences Clontech. The results obtained by
this method are closely related to those of the
reverse transcription-linked polymerase chain
reaction (RT-PCR) and real-time RT-PCR
(Camerer, 2000; Cho, 2002; Goidin, 2000; Hester,
2003). To investigate the long-lasting effects of
neonatal treatments, we measured gene expression
at 8 weeks of age, although the hyperactivity caused
by 6-OHDA lesions might be attenuated to control
levels (Zhang, 2002). The decrease in gene
expression observed here could not be due solely
to the lack of DA neurons because we observed
enhanced expression in several genes. Moreover,
no difference was found between treated and
control rats in the yield ofRNA/tissue weight or in
the integrity of the RNA in brain regions dissected
out in the present study.
The effects of6-OHDA lesions have been well
documented; 6-OHDA affects the survival and the
maintenance of DA neurons, thus triggering
compensatory responses of the DA system. Recent
studies with the DNA array technique demonstrated
that several genes, including pleiotrophin, glial-
derived neurotrophic factor, protein kinase A
subunit C, and cyclin-dependent kinase 5, were up-
regulated in the rat striatum after an injection of
6-OHDA into the substantia nigra (Hida, 2003;
Napolitano, 2002). Taken together, the changes in
gene expression observed here seem to be due to
DA-specific lesions and compensatory mechanisms.
We should note, however, that we performed intra-
cisternal injection of 6-OHDA and EDs on
postnatal day 5 and motor hyperactivity was
observed at 4 weeks of age. In previous studies
(Hida, 2003; Napolitano, 2002), 6-OHDA was
injected into the unilateral substantia nigra in the
rat at 4 or 12 weeks of age, which is an animal
model of Parkinson’s disease. Thus, the present
study is not comparable to these previous studies,
and it remains to be possible that the changes in
gene expression after neonatal treatment with 6-
OHDA and EDs are related to the mechanisms
underlying motor hyperactivity.
In rats with neonatal 6-OHDA lesions, the
expression of Glast was decreased in the mid-brain
and enhanced in the striatum. The findings suggest
that alterations in Glast, a high-affinity sodium-
dependent glial glutamate/aspartate transporter,
might play a part in the important role of motor
hyperactivity and/or compensatory mechanisms in
young adult rats with 6-OHDA lesions. In DEHP-
treated rats, however, Glast expression was
enhanced in the midbrain with no change in the
striatum; other EDs did not cause a change in
Glast in either region. In Grin 1, which encodes the
NMDA receptor 1, expression was decreased in
the midbrain and striatum by 6-OHDA. In the
midbrain, nonylphenol and DEHP, but not
bisphenol A and p-octylphenol, also caused a
decrease in the expression. In the striatum, DEHP
also caused a decrease in the expression. The
striatum is a region rich in NMDA receptors
(Gracy, 1999; Petralia, 1994; Tarazi, 1999), and
corticostriatal glutamatergic neurons stimulate DA
release from the striatum (Taber, 1993) viaNMDA
receptors (Ochi, 1995). Thus, the present results
suggest that glutamatergic transmission via NMDAMOTOR ACTIVITY AND GENE EXPRESSION IN THE RAT 73
receptors can be attenuated in the striatum during
early adulthood. Taken together, an inhibition of
glutamatergic transmission in the midbrain and
striatum may be involved in changes in motor
activity caused by 6-OHDA, nonyl-phenol, and
DEHP.
The finding that 6-OHDA lesions caused an
increase in Datl expression in the midbrain
supports the results of previous studies suggesting
an augmentation in the expression of the DA
transporter in patients with ADHD (Madras,
2002; Roman, 2001). The expression of Datl can
be increased in DA neurons that are resistant to
6-OHDA treatment and/or in non-DA elements
(Hoffman, 1998). On the contrary, a decrement of
Dat expression can be due to the lack of DAergic
terminals in the striatum. Bisphenol A caused a
decrease in Datl expression in the midbrain with
no changes caused by other environmental chemicals.
Possibly other EDs caused a deficit not only in the
DA system but also in other systems. The
expression of Drd4 was also enhanced in the
midbrain after 6-OHDA, which supports the
results of previous studies suggesting that D4
receptors are implicated in clinical ADHD
(DiMaio, 2003). The induction of Datl and Drd4
expression in the midbrain can contribute to the
efficiency of psychostimulants like methylphenidate
in motor hyperactivity. The effects of
psychostimulants on SMA should be further
investigated in rats receiving neonatal treatment
with EDs in comparison with animals with 6-
OHDA lesions.
After the 6-OHDA lesions, we also observed
alterations in the expression of several classes of
genes. Expression was increased in genes coding
cell receptors such as Pdgfrb, Insr, Galr2, and
Avpr2, and in cell-signaling extracellular
communication proteins, such as Npy, Tac2, Grp,
Fgfl0, Nppc, and lgfbp6 in the midbrain. In these
genes, the expression profiles in rats treated with
EDs were different from those obtained with
6-OHDA. The expression of Npy, however, was
also increased after DEHP treatment, and an
enhanced expression of Nppc was similarly found
after the injection of nonylphenol, p-octylphenol,
and DEHP. Among these, galanin has been
suggested to interact with DA neurons in the
midbrain (Counts, 2002) and striatum (Ericson,
1999; Tsuda, 1998). It was demonstrated that
arginine vasopression (Iqbal, 1995) and GRP
(Larsen, 1989) are expressed in the substantia
nigra. These peptides might be also involved in
motor hyperactivity and/or compensatory changes
with different roles in the regulation of the
mesostriatal system.
We studied gene expression in the midbrain
and striatum to investigate mechanisms underlying
motor hyperactivity. It was suggested, however,
that the frontal cortex and ventral striatum,
including the nucleus accumbens, play important
roles in behavior and cognition in ADHD (Sonuga-
Barke, 2002; 2003). A defect in neuronal circuits
required for reward-guided associative learning
and memory formation might be due to a deficit in
glutamate-evoked release in the nucleus accumbens
in ADHD patients (Russell, 2003). The frontal
cortex can also play an important role in ADHD
(Russell, 2002). Moreover, it was suggested that
the altered neurotransmission of noradrenaline and
serotonin is involved in ADHD and/or motor
hyperactivity (Blanc, 1994; Davids, 2002a). In the
present study, altered expression was not observed
in genes encoding adrenergic and serotonergic
elements although the Atlas Rat 1.2 (BD Bio-
sciences Clontech) contained several classes of
adrenergic and serotonergic receptors. Thus,
multiple gene expression should be further
investigated in the nucleus accumbens and in the
frontal cortex.
The present study has demonstrated motor
hyperactivity in rats neonatally treated with
6-OHDA and EDs. Among the EDs, phenols, but
http://www.bdbiosciences.com/clontech/atlas/genelists/index.
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not a phthalate, might cause the deficit in the
development of mesostriatal DA neurons. The
results of the DNA array suggest that the trans-
mission of glutamate, DA, and other factors
including neuropeptides, can be crucial in motor
hyperactivity and/or compensatory mechanisms by
the lack ofDA neurons. The alteration patterns of
gene expression by EDs differed from those of
6-OHDA, however, and these were not identical
among EDs. The results suggest that neonatal
treatment with EDs can provide an animal model
ofADHD in which clinical symptoms are pervasive.
The present study focusing on mesostriatal DA
neurons prompts further investigation of multiple
gene expression in the frontal cortex and ventral
striatum to understand the mesocorticolimbic
variants underlying ADHD.
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